eli lilly retatrutide press release 2024 2025 Lilly's triple-acting obesity drug hits goal in Phase 3 trial Eli Lilly says next-generation weight

J Pediatr Surg

Core+ is ideal if youre already taking GLP1s elsewhere and want structured nutrition and lifestyle support

Discontinued treatment, low maintenance dosage led to reduced effectiveness of GLP-1 medications on body weight and blood sugar levels A Cleveland Clinic study shows that semaglutide and tirzepatide injectable GLP-1 drugs for obesity produce smaller weight loss in a real-world setting because patients discontinue treatment or use lower maintenance dosages

J., & Weissman, I

Yerba Mate Tea (Ilex paraguariensis): a comprehensive review on chemistry, health implications, and technological considerations

Even when the molecule is not a GLP-1 receptor agonist in the strict sense, these products compete at the same clinical and payer decision points